Synergistic Effect of COX-2 Inhibitor on Paclitaxel-Induced Apoptosis in the Human Ovarian Cancer Cell Line OVCAR-3

Purpose Celecoxib, a highly selective cyclooxygenase-2 inhibitor, regulates apoptosis of several types of human cancer cells. The purpose of this study was to investigate whether celecoxib in combination with paclitaxel modulates apoptosis of ovarian cancer cells, and to identify the signal pathway by which celecoxib mediates apoptosis. Materials and Methods OVCAR-3 cells were exposed to paclitaxel (20 µM) in the absence or presence of celecoxib (10 µM). Cell viability was evaluated using a Cell Counting Kit-8 assay. Apoptosis was evaluated using Annexin-V/7-aminoactinomycin D staining and a cellular DNA fragmentation enzyme-linked immunosorbent assay. Caspase-3, -9, and cleavage of poly ADP-ribose polymerase (PARP) were determined by western blotting. Expression of nuclear factor-κB (NF-κB) and vascular endothelial growth factor (VEGF) and Akt activation were assessed using reverse transcriptase-polymerase chain reaction and western blotting. Results Celecoxib enhanced paclitaxel-induced growth inhibition of OVCAR-3 cells. Celecoxib significantly increased paclitaxel-induced apoptosis of OVCAR-3 cells. Pretreatment with celecoxib also increased activation of caspase-9, -3 and cleaved PARP following paclitaxel-treatment. Exposure of OVCAR-3 cells to celecoxib in combination with paclitaxel resulted in downregulation of NF-κB activation and VEGF expression. Furthermore, combining celecoxib and paclitaxel inhibited phosphorylation of Akt. Conclusion OVCAR-3 cells were sensitized to paclitaxel-induced apoptosis by celecoxib through downregulation of NF-κB and Akt activation, suggesting that celecoxib may work synergistically with paclitaxel to inhibit different targets and ultimately produce anticancer effects. Combining celecoxib with paclitaxel may prove beneficial in the clinical treatment of ovarian cancer.

[1]  R. Chen,et al.  TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. , 2006, Cancer research.

[2]  W. Grizzle,et al.  Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  F. Ognibene,et al.  Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. , 1994, Journal of the National Cancer Institute.

[4]  Douglas B. Evans,et al.  The Nuclear Factor-κB RelA Transcription Factor Is Constitutively Activated in Human Pancreatic Adenocarcinoma Cells , 1999 .

[5]  D. Huntsman,et al.  Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours , 2005, Breast Cancer Research.

[6]  A. Letai,et al.  Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. , 2008, Cancer research.

[7]  Yi Huang,et al.  IκB Kinase Activation Is Involved in Regulation of Paclitaxel-Induced Apoptosis in Human Tumor Cell Lines , 2002 .

[8]  Y. Song,et al.  Akt Involvement in Paclitaxel Chemoresistance of Human Ovarian Cancer Cells , 2007, Annals of the New York Academy of Sciences.

[9]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[10]  N. Maggiano,et al.  Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Testa,et al.  Inhibition of Inhibitor of Nuclear Factor-κB Phosphorylation Increases the Efficacy of Paclitaxel in in Vitro and in Vivo Ovarian Cancer Models , 2004, Clinical Cancer Research.

[12]  Yi Huang,et al.  IkappaB kinase activation is involved in regulation of paclitaxel-induced apoptosis in human tumor cell lines. , 2002, Molecular pharmacology.

[13]  Robert C. Bast,et al.  Ovarian cancer: screening, treatment, and followup. , 1995, NIH consensus statement.

[14]  Jing Yang,et al.  Preventing chemoresistance of human breast cancer cell line, MCF-7 with celecoxib , 2010, Journal of Cancer Research and Clinical Oncology.

[15]  Kazuhiro Takahashi,et al.  Inhibition of NFκB Increases the Efficacy of Cisplatin in in Vitro and in Vivo Ovarian Cancer Models* , 2004, Journal of Biological Chemistry.

[16]  D. Schrump,et al.  Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway. , 2004, The Journal of thoracic and cardiovascular surgery.

[17]  M. Karamouzis,et al.  PPAR-gamma is expressed and NF-kB pathway is activated and correlates positively with COX-2 expression in stromal myofibroblasts surrounding colon adenocarcinomas , 2006, Journal of Cancer Research and Clinical Oncology.

[18]  Gong Yang,et al.  The Biphasic Role of NF-κB in Progression and Chemoresistance of Ovarian Cancer , 2011, Clinical Cancer Research.

[19]  W. Vainchenker,et al.  Inhibition of the erythropoietin-induced erythroid differentiation by granulocyte-macrophage colony-stimulating factor in the human UT-7 cell line is not due to a negative regulation of the erythropoietin receptor. , 1996, Blood.

[20]  S. Grösch,et al.  COX‐2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX‐2 inhibitor celecoxib , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  J. Morrow,et al.  A Phase II Study of Celecoxib in Combination with Paclitaxel, Carboplatin, and Radiotherapy for Patients with Inoperable Stage IIIA/B Non–Small Cell Lung Cancer , 2009, Clinical Cancer Research.

[22]  J. Long,et al.  Cyclooxygenase-2 promotes angiogenesis by increasing vascular endothelial growth factor and predicts prognosis in gallbladder carcinoma. , 2005, World journal of gastroenterology.

[23]  R. DuBois,et al.  The role of cyclooxygenases in inflammation, cancer, and development , 1999, Oncogene.

[24]  J. McCubrey,et al.  The novel NF-κB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism. , 2012, Cancer letters.

[25]  M. Altinoz,et al.  NF-kappaB, macrophage migration inhibitory factor and cyclooxygenase-inhibitions as likely mechanisms behind the acetaminophen- and NSAID-prevention of the ovarian cancer. , 2004, Neoplasma.

[26]  NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. , 1995, JAMA.

[27]  R. Parker,et al.  A phase 2 pilot trial of low‐dose, continuous infusion, or “metronomic” paclitaxel and oral celecoxib in patients with metastatic melanoma , 2010, Cancer.